Skip to main content

Clinical Trials & Results

With every trial, we aim to solve challenges and unlock possibilities. 

Our trials adhere to the highest standards of safety and equity, and our commitment to advancing healthcare is reflected in our rigorous study protocols and the relentless pursuit of new, effective treatments.

    • Ongoing Clinical Trials & Studies

      Specialty Medicines

      Study ID

      Study Description

      Intervention

      Study Phase/Type

      Recruitment Status* / ClinicalTrials.gov Identifier (if applicable)

      EN3835-309 PFI

      A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI)

      Collagenase clostridium histolyticum EN3835

      Phase 3/ Interventional

      Recruiting
      NCT06151197

    • Completed Clinical Trials & Studies

      In the last 5 years

      Specialty Medicines

      Study ID

      Study Description

      Study Treatment

      Clinical Study Results

      EN3225-001

      Open-Label Pilot Study Assessing the Efficacy and Safety of New Formulations of Percocet® in the Treatment of Low Back Pain

      PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets

      PDF

      EN3225-002

      A Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Study of the Safety and Efficacy of Low-dose Percocet® Compared to OxyContin® in Patients With Acute Pain Following Third Molar Extraction

      PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets

      PDF

      EN3225-003

      A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Safety and Efficacy of Low-Dose Percocet® in Patients With Acute Pain Following Third Molar Extraction

      PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets

      PDF

      EN3835-210

      A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

      Collagenase clostridium histolyticum EN3835

      Completed
      NCT04496167

      EN3835-222

      A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

      Collagenase clostridium histolyticum EN3835

      Completed
      NCT05152173

      EN3835-223

      An Observational, Double-blind (Sponsor Open), Long-term Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to Placebo in the Treatment of Adhesive Capsulitis of the Shoulder (Frozen Shoulder)

      No treatment to be administered

      Completed
      NCT04680156

      EN3835-306

      A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis.

      Collagenase clostridium histolyticum EN3835

      Completed
      NCT05254457

      EN3000-101

      An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products

      AVEED®
      TESTIM®
      FORTESTA®

      Completed
      NCT04456296

      EN3835-227 PFA

      A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Assess The Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)

      Collagenase clostridium histolyticum EN3835

      Completed
      NCT06169319

      Sterile Injectables

      Study ID

      Study Description

      Study Treatment

      Clinical Study Results

      PS4229-101

      A Phase 1, Open-Label, Two-Arm, Parallel-Group, Pharmacokinetic Study on Plasma Clearance of Vasopressin in Healthy Volunteers

      Vasostrict® (vasopressin injection, USP)

      Completed
      NCT04093050